

6. References

- American College of Physicians (1992) Guidelines for counselling postmenopausal women about preventive hormone therapy. *Ann. intern. Med.*, **117**, 1038–1041
- Anderson, T.J., Ferguson, D.J. & Raab, G.M. (1982) Cell turnover in the 'resting' human breast: Influence of parity, contraceptive pill, age and laterality. *Br. J. Cancer*, **46**, 376–382
- Anderson, T.J., Battersby, S., King, R.J.B., McPherson, K. & Goings, J.J. (1989) Oral contraceptive use influences resting breast proliferation. *Hum. Pathol.*, **20**, 1139–1144
- Beresford, S.A.A., Weiss, N.S., Voigt, L.F. & McKnight, B. (1997) Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. *Lancet*, **349**, 458–461
- Bergkvist, L., Adami, H.O., Persson, I., Hoover, R. & Schairer, C. (1989) The risk of breast cancer after estrogen and estrogen–progesterin replacement. *New Engl. J. Med.*, **321**, 293–297
- Bhattacharya, D., Redkar, A., Mitra, I., Sutaria, U. & MacRae, K.D. (1997) Oestrogen increases S-phase fraction and oestrogen and progesterone receptors in human cervical cancer *in vivo*. *Br. J. Cancer*, **75**, 554–558
- Braasch, H.V., Frederiksen, M.C. & Chaterton, R.T. (1988) Metabolism and pharmacokinetics of progesterone in the cynomolgus monkey (*Macaca fascicularis*). *Steroids*, **52**, 279–294

- Brinton, L.A., Hoover, R.N. & the Endometrial Cancer Collaborative Group (1993) Estrogen replacement therapy and endometrial cancer risk: Unresolved issues. *Obstet. Gynecol.*, **81**, 265–271
- British Medical Association (1997) Female sex hormones. In: *British National Formulary*, Vol. 34, London, Royal Pharmaceutical Society of Great Britain, pp. 313–321
- Bush, T.L. & Barrett-Connor, E. (1985) Non contraceptive estrogen use and cardiovascular disease. *Epidemiol. Rev.*, **7**, 80–104
- Cameron, S.T., Critchley, H.O., Glasier, A.F., Williams, A.R. & Baird, D.T. (1997) Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women. *Br. J. Obstet. Gynaecol.*, **104**, 1184–1190
- Campagnoli, C., Biglia, N., Lanza, M.G., Lesca, L., Peris, C. & Sismondi, P. (1994) Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. *Maturitas*, **19**, 25–31
- Cerin, A., Heldaas, K. & Moeller, B. (1996) Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy. The Scandinavian Long Cycle Study Group (Letter to the Editor). *New Engl. J. Med.*, **334**, 668–669
- Cline, J.M., Soderqvist, G., von Schoultz, E., Skoog, L. & von Schoultz, B. (1996) Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. *Am. J. Obstet. Gynecol.*, **174**, 93–100
- Colditz, G.A., Stampfer, M.J., Willett, W.C., Hunter, D.J., Manson, J.E., Hennekens, C.H., Rosner, B.A. & Speizer, F.E. (1992) Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. *Cancer Causes Control*, **3**, 433–439
- Colditz, G.A., Hankinson, S.E., Hunter, D.J., Willett, W.C., Manson, J.E., Stampfer, M.J., Hennekens, C. & Rosner, B. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. *New Engl. J. Med.*, **332**, 1589–1593
- Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. *Lancet*, **350**, 1047–1059
- Ettinger, B., Selby, J., Citron, J.T., Bangessel, A., Ettinger, V.M. & Hendrickson, M.R. (1994) Cyclic hormone replacement therapy using quarterly progestin. *Obstet. Gynecol.*, **83**, 693–700
- Ewertz, M. (1988) Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. *Int. J. Cancer*, **42**, 832–838
- Finnegan, L.P., Rossouw, J. & Harlan, W.R. (1995) A peppy response to PEPI results. *Nature Med.*, **1**, 205–206
- Fotherby, K. (1994) Pharmacokinetics and metabolism of progestins in humans. In: Goldzieher, J.W. & Fotherby, K., eds, *Pharmacology of the Contraceptive Steroids*, New York, Raven Press, pp. 99–126
- Fotherby, K. (1996) Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. *Contraception*, **54**, 59–69

- Gambrell, R.D. (1986) Prevention of endometrial cancer with progestogens. *Maturitas*, **8**, 159–168
- Gangrade, N.K., Boudinot, F.D. & Price, J.C. (1992) Pharmacokinetics of progesterone in ovariectomized rat after single dose intravenous administration. *Biopharm. Drug Disposition*, **13**, 703–709
- Going, J.J., Anderson, T.J., Battersby, S. & MacIntyre, C.C. (1988) Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. *Am. J. Pathol.*, **130**, 193–204
- Hammond, C.B., Jelovsek, F.R., Lee, K.L., Creasman, W.T. & Parker, R.T. (1979) Effects of long-term estrogen replacement therapy. II. Neoplasia. *Am. J. Obstet. Gynecol.*, **133**, 537–547
- Hirvonen, E. (1996) Progestins. *Maturitas*, **23** (Suppl.), S13–S18
- Hirvonen, E., Allonen, H., Anttila, M., Kulmala, Y., Ranta, T., Rautiainen, H., Sipila, P. & Ylostalo, P. (1995) Oral contraceptive containing natural estradiol for premenopausal women. *Maturitas*, **21**, 27–32
- Honjo, H., Ishihara, M., Osawa, Y., Kirdani, R.Y. & Sandberg, A.A. (1976) The metabolic fate of chlormadinone acetate in the baboon. *Steroids*, **27**, 79–98
- Hunt, K., Vessey, M., McPherson, K. & Coleman, M. (1987) Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. *Br. J. Obstet. Gynaecol.*, **94**, 620–635
- Hunt, K., Vessey, M. & McPherson, K. (1990) Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis. *Br. J. Obstet. Gynaecol.*, **97**, 1080–1086
- IARC (1979) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Vol. 21, *Sex Hormones (II)*, Lyon
- Jick, S.S., Walker, A.M. & Jick, H. (1993) Oral contraceptives and endometrial cancer. *Obstet. Gynecol.*, **82**, 931–935
- Johanisson, E., Holinka, C.F. & Arrenbrecht, S. (1997) Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: Effects on the endometrium. *Int. J. Fertil.*, **42** (Suppl. 2), 388–398
- Johansson, E.D.B., Johansson, P.B. & Rasmussen, S.N.A. (1986) MPA pharmacokinetics after oral administration. *Acta pharmacol. toxicol.*, **58**, 311–317
- Kaufman, D.W., Kelly, J.P., Welch, W.R., Rosenberg, L., Stolley, P.D., Warshauer, M.E., Lewis, J., Woodruff, J. & Shapiro, S. (1989) Noncontraceptive estrogen use and epithelial ovarian cancer. *Am. J. Epidemiol.*, **130**, 1142–1151
- Kaufman, D.W., Palmer, J.R., de Mouzon, J., Rosenberg, L., Stolley, P.D., Warshauer, M.E., Zauber, A.G. & Shapiro, S. (1991) Estrogen replacement therapy and the risk of breast cancer: Results from the case-control surveillance study. *Am. J. Epidemiol.*, **134**, 1375–1385
- Kelly, J.J., Rajkovic, I.A., O'Sullivan, A.J., Sernia, C. & Ho, K.K.Y. (1993) Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. *Clin. Endocrinol.*, **39**, 561–567
- Kelsey, J.L., Gammon, M.D. & John, E.M. (1993) Reproductive factors and breast cancer. *Epidemiol. Rev.*, **15**, 36–47
- Kennedy, D.L., Baum, C. & Forbes, M.B. (1985) Noncontraceptive estrogens and progestins: Use patterns over time. *Obstet. Gynecol.*, **65**, 441–446

- Key, T.J. & Pike, M.C. (1988) The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. *Eur. J. Cancer clin. Oncol.*, **24**, 29–43
- King, R.J.B. & Whitehead, M.I. (1986) Assessment of the potency of orally administered progestins in women. *Fertil. Steril.*, **46**, 1062–1066
- Kleinman, R.L. (1990) *Hormonal Contraception*, London, IPPF Medical Publications
- Kowalski, W.B., Chatterton, R.T., Kazer, R.R. & Severini, T.A. (1996) Disappearance and unexpected reappearance of progesterone in the circulation of the monkey: Novel hormone kinetics. *J. Physiol.*, **493**, 877–884
- Kreitmman, B., Bugat, R. & Bayard, F. (1979) Estrogen and progestin regulation of the progesterone receptor concentration in human endometrium. *J. clin. Endocrinol. Metab.*, **49**, 926–929
- Kuhl, H. (1990) Pharmacokinetics of oestrogens and progestogens. *Maturitas*, **12**, 171–197
- Kumasaka, T., Itoh, E., Watanabe, H., Hoshino, K., Yoshinaka, A. & Masawa, N. (1994) Effects of various forms of progestin on the endometrium of the estrogen-primed, ovariectomized rat. *Endocrine J.*, **41**, 161–169
- Lancaster, T., Surman, G., Lawrence, M., Mant, D., Vessey, M., Thorogood, M., Yudkin, P. & Daly, E. (1995) Hormone replacement therapy: Characteristics of users and non-users in a British general practice cohort identified through computerised prescribing records. *J. Epidemiol. Community Health*, **49**, 389–394
- Lane, G., Siddle, N.C., Ryder, T.A., Pryse-Davies, J., King, R.J.B. & Whitehead, M.I. (1986) Effects of dydrogesterone on the oestrogenized postmenopausal endometrium. *Br. J. Obstet. Gynaecol.*, **93**, 55–62
- Li, J.J., Li, S.A., Oberley, T.D. & Parsons, J.A. (1995) Carcinogenic activities of various steroidal and nonsteroidal estrogens in the hamster kidney: Relation to hormonal activity and cell proliferation. *Cancer Res.*, **55**, 4347–4351
- Longacre, T.A. & Bartow, S.A. (1986) A correlative morphologic study of human breast and endometrium in the menstrual cycle. *Am. J. Surg. Pathol.*, **10**, 382–393
- Luo, S., Stojanovic, M., Labrie, C. & Labrie, F. (1997) Inhibitory effect of the novel anti-estrogen EM-800 and medroxyprogesterone acetate on estrone-stimulated growth of dimethylbenz[*a*]anthracene-induced mammary carcinoma in rats. *Int. J. Cancer*, **73**, 580–586
- Maddison, J. (1973) Hormone replacement therapy for menopausal symptoms (Letter to the Editor). *Lancet*, **i**, 1507
- Maxson, W.S. & Hargrove, J.T. (1985) Bioavailability of oral micronized progesterone. *Fertil. Steril.*, **44**, 622–626
- Morville, R., Dray, F., Reynier, J. & Barrat, J. (1982) The bioavailability of natural progesterone given by mouth. Measurement of steroid concentrations in plasma, endometrium and breast tissue. *J. Gynécol. Obstét. Biol. Reprod. (Paris)*, **11**, 355–363 (in French)
- Nachtigall, L.E., Nachtigall, R.H., Nachtigall, R.D. & Beckman, E.M. (1979) Estrogen replacement therapy. I. A 10-year prospective study in the relationship to osteoporosis. *Obstet. Gynecol.*, **53**, 277–281
- Newcomb, P.A. & Storer, B.E. (1995) Postmenopausal hormone use and risk of large-bowel cancer. *J. natl Cancer Inst.*, **87**, 1067–1071

- Newcomb, P.A., Longnecker, M.P., Storer, B.E., Mittendorf, R., Baron, J., Clapp, R.W., Bogdan, G. & Willett, W.C. (1995) Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. *Am. J. Epidemiol.*, **142**, 788–795
- Østerlind, A., Tucker, M.A., Stone, B.J. & Jensen, O.M. (1988) The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. *Int. J. Cancer*, **42**, 821–824
- Ottoson, U.B., Carlstrom, K., Damber, J.E. & von Schoultz, B. (1984) Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration. *Br. J. Obstet. Gynaecol.*, **91**, 1111–1119
- Pannuti, F., Camaggi, C.M., Strocchi, E., Giovannini, M., DiMarco, A.R. & Costanti, B. (1982) MPA relative availability after single high dose administration. *Cancer Treat. Rep.*, **66**, 2043–2049
- Paterson, M.E.L., Wade-Evans, T., Sturdee, D.W., Thom, M.H. & Studd, J.W.W. (1980) Endometrial disease after treatment with oestrogens and progestogens in the climacteric. *Br. med. J.*, **i**, 822–824
- Persson, I., Adami, H.-O., Bergkvist, L., Lindgren, A., Pettersson, B., Hoover, R. & Schairer, C. (1989) Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study. *Br. med. J.*, **298**, 147–151
- Persson, I., Yuen, J., Bergkvist, L. & Schairer, C. (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy—Long-term follow-up of a Swedish cohort. *Int. J. Cancer*, **67**, 327–332
- Persson, I., Bergkvist, L., Lindgren, C. & Yuen, J. (1997) Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: Evidence of confounding by exposure characteristics. *J. clin. Epidemiol.*, **50**, 611–618
- Pike, M.C., Peters, R.K., Cozen, W., Probst-Hensch, N.M., Felix, J.C., Wan, P.C. & Mack, T.M. (1997) Estrogen-progestin replacement therapy and endometrial cancer. *J. natl Cancer Inst.*, **89**, 1110–1116
- Postmenopausal Estrogen/Progestin Interventions Trial (PEPI) (1996) Effects of hormone replacement therapy on endometrial histology in postmenopausal women. *J. Am. med. Assoc.*, **275**, 370–375
- Potten, C.S., Watson, R.J., Williams, G.T., Tickle, S., Roberts, S.A., Harris, M. & Howell, A. (1988) The effect of age and menstrual cycle upon proliferative activity of the normal human breast. *Br. J. Cancer*, **58**, 163–170
- Preston-Martin, S., Pike, M.C., Ross, R.K., Jones, P.A. & Henderson, B.E. (1990) Increased cell division as a cause of human cancer. *Cancer Res.*, **50**, 7415–7421
- Risch, H.A. & Howe, G.R. (1994) Menopausal hormone usage and breast cancer in Saskatchewan: A record-linkage cohort study. *Am. J. Epidemiol.*, **139**, 670–683
- Risch, H.A. & Howe, G.R. (1995) Menopausal hormone use and colorectal cancer in Saskatchewan: A record linkage cohort study. *Cancer Epidemiol. Biomarkers Prev.*, **4**, 21–28
- Sakamoto, S., Kudo, H., Suzuki, S., Mitamura, T., Sassa, S., Kuwa, K., Chun, Z., Yoshimura, S., Maemura, M., Nakayama, T. & Shinoda, H. (1997) Additional effects of medroxyprogesterone acetate on mammary tumors in oophorectomized, estrogenized, DMBA-treated rats. *Anti-cancer Res.*, **17**, 4583–4588

- Schairer, C., Byrne, C., Keyl, P.M., Brinton, L.A., Sturgeon, S.R. & Hoover, R.N. (1994) Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). *Cancer Causes Control*, **5**, 491-500
- Schleusener, A., Nishino, Y., Albring, M., Neumann, F. & Beier S. (1980) Endocrine profile of cyproterone acetate metabolite and its potential clinical use. *Acta endocrinol.*, **234S**, 94-106
- Shi, Y.E., He, C.H., Gu, J. & Fotherby, K. (1987) Pharmacokinetics of norethisterone in humans. *Contraception*, **35**, 465-475
- Siddle, N.C., Townsend, P.T., Young, O., Minardi, J., King, R.J.B. & Whitehead, M.I. (1982) Dose-dependent effects of synthetic progestins on the biochemistry of the estrogenized post-menopausal endometrium. *Acta obstet. gynecol. scand.*, **Suppl. 106**, 17-22
- Simon, J.A., Robinson, D.E., Andrews, M.C., Hildebrand, J.R., Rocci, M.L., Jr, Blake, R.E. & Hodgen, G.D. (1993) The absorption of oral micronized progesterone: The effect of food dose proportionality, and comparison with intramuscular progesterone. *Fertil. Steril.*, **60**, 26-33
- Söderqvist, G., von Schoultz, B., Tani, E. & Skoog, L. (1993) Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. *Am. J. Obstet. Gynecol.*, **168**, 874-879
- Speroff, L., Rowan, J., Symons, J., Genant, H. & Wilborn, W. for the CHART Study Group (1996) The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study). A randomized controlled trial. *J. Am. med. Assoc.*, **276**, 1397-1403
- Stanford, J.L. & Thomas, D.B. (1993) Exogenous progestins and breast cancer. *Epidemiol. Rev.*, **15**, 98-107
- Stanford, J.L., Weiss, N.S., Voigt, L.F., Daling, J.R., Habel, L.A. & Rossing, M.A. (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. *J. Am. med. Assoc.*, **274**, 137-142
- Studd, J.W.W. (1976) Hormone implants in the climacteric syndrome. In: Campbel, S., ed., *The Management of the Menopause and the Post-menopausal Years*, Lancaster, MTP Press Ltd, pp. 383-385
- Sturdee, D.W., Wade-Evans, T., Paterson, M.E., Thom, M. & Studd, J.W. (1978) Relations between bleeding pattern, endometrial histology, and oestrogen treatment in menopausal women. *Br. med. J.*, **i**, 1575-1577
- Suhonen, S., Haukkamaa, M., Holmström, T., Lähteenmäki, P. & Rutanen, E.-M. (1996) Endometrial response to hormone replacement therapy as assessed by expression of insulin-like growth factor-binding protein-1 in the endometrium. *Fertil. Steril.*, **65**, 776-782
- Suvanto-Luukkonen, E., Sundström, H., Penttinen, J., Kauppila, A. & Rutanen, E.-M. (1995) Insulin-like growth factor-binding protein-1: A biochemical marker of endometrial response to progestin during hormone replacement therapy. *Maturitas*, **22**, 255-262
- Thom, M.H., White, P.J., Williams, R.M., Sturdee, D.W., Paterson, M.E., Wade-Evans, T. & Studd, J.W. (1979) Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy. *Lancet*, **ii**, 455-457
- Townsend, J. (1998) Hormone replacement therapy: Assessment of present use, costs and trends. *Br. J. gen. Pract.*, **48**, 955-958

- Troisi, R., Schairer, C., Chow, W.-H., Schatzkin, A., Brinton, L.A. & Fraumeni, J.F., Jr (1997) A prospective study of menopausal hormones and risk of colorectal cancer (United States). *Cancer Causes Control*, **8**, 130–138
- Vogel, P.M., Georgiade, N.G., Fetter, B.F., Vogel, F.S. & McCarty, K.S., Jr (1981) The correlation of histologic changes in the human breast with the menstrual cycle. *Am. J. Pathol.*, **104**, 23–34
- Voigt, L.F., Weiss, N.S., Chu, J., Daling, J.R., McKnight, B. & van Belle, G. (1991) Progesterone supplementation of exogenous oestrogens and risk of endometrial cancer. *Lancet*, **338**, 274–277
- Whitehead, M.I., Townsend, P.T., Gill, D.K., Collins, W.P. & Campbell, S. (1980) Absorption and metabolism of oral progesterone. *Br. med J.*, **i**, 825–827
- Whitehead, M.I., Townsend, P.T., Pryse-Davies, J., Ryder, T.A. & King, R.J.B. (1981) Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. *New Engl. J. Med.*, **305**, 1599–1605
- Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. *J. Am. med. Assoc.*, **273**, 199–208
- Yang, C.P., Daling, J.R., Band, P.R., Gallagher, R.P., White, E. & Weiss, N.S. (1992) Noncontraceptive hormone use and risk of breast cancer. *Cancer Causes Control*, **3**, 475–479
- Yuen, J., Persson, I., Bergkvist, L., Hoover, R., Schairer, C. & Adami, H.O. (1993) Hormone replacement therapy and breast cancer mortality in Swedish women: Results after adjustment for 'healthy drug-user' effect. *Cancer Causes Control*, **4**, 369–374
- Ziel, H.K. & Finkle, W.D. (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. *New Engl. J. Med.*, **293**, 1167–1170